BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 32783372)

  • 1. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
    Hirai T; Inomata M; Minatoyama S; Hashizume M; Takata N; Hayashi K; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Tanaka S; Noguchi A; Sato T
    In Vivo; 2024; 38(3):1509-1511. PubMed ID: 38688637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab.
    Kachi S; Sumitomo S; Oka H; Hata A; Ohmura K
    Front Immunol; 2024; 15():1400097. PubMed ID: 38799449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous arteritis combined with antiphospholipid syndrome associated with the use of immune checkpoint inhibitors in a patient with a metastatic lung adenocarcinoma.
    Hayashi M; Shiraishi K; Yoshida S; Yatsuzuka K; Kohri N; Kuroo Y; Horie K; Muto J; Murakami M; Fujisawa Y
    J Dermatol; 2024 May; 51(5):e166-e167. PubMed ID: 38063285
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint inhibitor associated diarrhoea.
    Al-Hussainy A; Adams J; Simmons J; Kennedy J
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
    Kim AE; Lou KW; Giobbie-Hurder A; Chang K; Gidwani M; Hoebel K; Patel JB; Cleveland MC; Singh P; Bridge CP; Ahmed SR; Bearce BA; Liu W; Fuster-Garcia E; Lee EQ; Lin NU; Overmoyer B; Wen PY; Nayak L; Cohen JV; Dietrich J; Eichler A; Heist R; Krop I; Lawrence D; Ligibel J; Tolaney S; Mayer E; Winer E; Perrino CM; Summers EJ; Mahar M; Oh K; Shih HA; Cahill DP; Rosen BR; Yen YF; Kalpathy-Cramer J; Martinez-Lage M; Sullivan RJ; Brastianos PK; Emblem KE; Gerstner ER
    Neuro Oncol; 2024 May; 26(5):965-974. PubMed ID: 38070147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study.
    Li P; Huang L; Han R; Tang M; Fei G; Zeng D; Wang R
    Clin Transl Med; 2024 Jun; 14(6):e1673. PubMed ID: 38840331
    [No Abstract]   [Full Text] [Related]  

  • 8. Synchronous Endobronchial Carcinoid Tumor and Adenocarcinoma of the Lung: A Case Report and Review of the Literature.
    Hajjaj N; Abdulelah M; Alsharif NM; Shamieh E; Bader H
    Cureus; 2021 Jun; 13(6):e15977. PubMed ID: 34336469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary lung adenocarcinoma mimicking recurrent pneumonia in a young adult.
    Joshi T; Rahman Y; Yeung HM
    BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37597859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons in clinical reasoning - pitfalls, myths, and pearls: shoulder pain as the first and only manifestation of lung cancer.
    DĂ­az-Abad J; Aranaz-Murillo A; Mayayo-Sinues E; Canchumanya-Huatuco N; Schaye V
    Diagnosis (Berl); 2024 May; 11(2):212-217. PubMed ID: 38387019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
    Richters A; Yildirim H; Booth CM; Vera Badillo FE; Kiemeney LALM; Aben KKH
    JAMA Oncol; 2023 Aug; 9(8):1144-1147. PubMed ID: 37289470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases.
    Cheng H; Lei BF; Peng PJ; Lin YJ; Wang XJ
    J Surg Res; 2017 May; 211():215-222. PubMed ID: 28501120
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.